PRESS RELEASE
News
-
-
PRESS RELEASE
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Bausch Health Companies Inc. and Solta Medical have announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA), marking a significant milestone for Solta Medical and opening up significant opportunities in the Chinese market. The approval represents a substantial achievement for the R&D and Regulatory Teams, signifying continued growth for the Thermage technology. The non-invasive treatment, which uses radiofrequency technology to tighten and improve the texture of the skin, has seen over two million treatments globally and is now set to continue its growth in China. The approval paves the way for delivering proven technology to the Chinese market and signifies a crucial breakthrough in the medical aesthetics market. -
PRESS RELEASE
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Bausch Health Companies Inc. and Solta Medical announce the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). This approval represents a significant breakthrough in one of the largest medical aesthetics markets, allowing the companies to continue the momentum of the growth of Thermage in China. The non-invasive treatment, Thermage, is a versatile and effective technology that can be used on all skin types and genders, delivering exceptional results for patients. For more information, visit www.bauschhealth.com and www.solta.com. -
PRESS RELEASE
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals presented oral arguments at the U.S. Court of Appeals for the Federal Circuit regarding the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued following the oral arguments. The company continues to advocate for the safety of patients benefiting from XIFAXAN® (rifaximin) 550 mg tablets, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea. Salix Pharmaceuticals focuses on the prevention and treatment of gastrointestinal diseases for over 30 years and markets its products to U.S. health care providers. On the other hand, Bausch Health Companies Inc. is a global diversified pharmaceutical company with a mission to improve people's lives through various health care products, primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The news release contains forward-looking statements about Bausch Health's future performance and the appeal with respect to intellectual property. The actual results are subject to certain risks and uncertainties. For more information, visit www.bauschhealth.com and connect with them on Twitter and LinkedIn. -
-
-
PRESS RELEASE
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
Salix Pharmaceuticals, Bausch Health Companies Inc., U.S. Pain Foundation, and IFFGD collaborate to establish the first annual Opioid-Induced Constipation (OIC) Awareness Day to raise awareness about the often-overlooked side effect of opioids and provide a platform for patients, caregivers, and healthcare providers to discuss and address OIC -
-
-
